1	ACCEPTABILITY AND UTILISATION OF PATIENT-INITIATED FOLLOW-UP
2	(PIFU) FOR ENDOMETRIAL CANCER AMONGST WOMEN FROM DIVERSE
3	ETHNIC AND SOCIAL BACKGROUNDS: A MIXED METHODS STUDY
4	
5	¹ P Kumarakulasingam BSc (medical student), ² H McDermott PhD (lecturer in health
6	psychology), ³ N Patel (clinical nurse specialist), ³ L Boutler (clinical nurse specialist),
7	⁴ DG Tincello MD (consultant gynaecologist), ³ D Peel FRCR (consultant clinical
8	oncologist), ^{1,3} EL Moss PhD (consultant gynaecological oncologist)
9	
10	¹ Department of Cancer Studies, University of Leicester, Leicester,
11	² School of Sport, Exercise and Health Sciences, Loughborough University,
12	³ Department of Gynaecological Oncology, University Hospitals of Leicester
13	⁴ Department of Health Sciences, University of Leicester, Leicester
14	
15	Address for correspondence:
16	Dr Esther Moss PhD, ORCID 0000-0002-2650-0172, Department of Cancer Studies,
17	University of Leicester, Leicester Royal Infirmary, Leicester, LE2 7LX. Email:
18	<u>em321@le.ac.uk</u> . Tel: 0044 2584861
19	
20	FUNDING
21	This study was funded by the University of Leicester and the University Hospitals of Leicester
22	Gynaecological Gynaecological Cancer Research fund.
23	
24 25	CONFLICT OF INTEREST STATEMENT
23 26 27	None of the authors report conflict of interest.

28 ABSTRACT

29 Introduction

A shift in focus towards risk stratification and survivorship in early stage endometrial cancer
(EC) has led to the replacement of hospital follow-up (HFU) with patient-initiated follow-up
(PIFU) schemes.

33 Methods

A mixed-methods study was undertaken prospectively to investigate utility and patient
 satisfaction with a newly introduced PIFU scheme.

36 **Results**

37 228 women were enrolled onto PIFU in the first 18 months, median age 65 years (range 42-90 38 years). Twenty-four (10.5%) women were non British-White ethnicity. Forty-five women 39 contacted the Clinical Nurse Specialist (CNS) at least once (19.7%), the primary reason being 40 vaginal bleeding/discharge (42%). Contact was greater in first six months on the scheme 41 compared to the second six months, and women who made contact were significantly younger 42 than those who did not (57 years versus 65 years, p<0.001).</p>

43 Conclusions

PIFU appears to be well received by the majority of women. Although many of the CNS contacts were due to physical symptoms, a number were for psychological support or reassurance. Younger women had greater CNS contact indicating that they may benefit from a greater level support. Patient feedback of the PIFU scheme was positive, with many women reporting that it enabled them to have more control over their own health.

49

50 KEYWORDS: Endometrial cancer; follow up; patient-initiated; quality of life; patient
 51 satisfaction

53 INTRODUCTION

54 The incidence of endometrial cancer (EC) in the UK has increased by 65% over the past 40 55 years making it not only the most common gynaecological cancer but the fourth most common 56 malignancy in women, accounting for 3% of all new cancer diagnoses (UK). The majority of cases are diagnosed with early stage disease, which carries a good long-term prognosis with 5-57 58 year disease-specific survivals in excess of 95% (Amant et al., 2005; UK). It is a disease 59 typically affecting older women with the majority being over the age of 70 years at diagnosis 60 and having co-morbidities, in particular obesity, diabetes and cardio-vascular disease (Parkin, 61 Boyd, & Walker, 2011).

62

63 Women diagnosed with an endometrial cancer have been traditionally followed-up through 64 regular hospital review by a specialist gynaecological oncologist after completing their treatment (Colombo et al., 2011). Hospital follow-up (HFU) typically involves women being 65 66 reviewed routinely by doctors and/or nurses who conduct a physical examination. The rationale 67 for attending HFU is surveillance for cancer recurrence thus enabling early detection, prompt 68 management and as a result a better long-term prognosis. The period of review has historically 69 been for a minimum of five years since the majority of cancer recurrences occur within three 70 years post treatment (Colombo et al., 2011). The role of routine follow-up in early stage, low-71 risk endometrial cancer (EC) however has been questioned since it does not appear to have an 72 impact of long-term survival (Gadducci, Cosio, Fanucchi, Cristofani, & Genazzani, 2000; 73 Owen & Duncan, 1996; Yoshiba et al., 2016). In light of the rising incidence, low recurrence 74 rate, population demographics and the lack clear clinical benefit of hospital follow-up in such cases, alternative follow-up schedules (Salani et al., 2011) and models have been developed, 75 76 for example telephone follow-up (TFU) (Beaver et al., 2016) and patient-initiated follow-up 77 (PIFU).

78

PIFU, as the name suggests, is where patients are not routinely seen in hospital but instead have open access to Clinical Nurse Specialists (CNS) whom they can contact should they have concerns or if/when symptoms arise. The first UK national survey on the follow-up of gynaecological cancer patients reported that out of all the available follow-up schemes, PIFU was used instead of or as an adjunct to existing follow up models by 32% of the centres that

responded (Leeson, Stuart, Sylvestre, Hall, & Whitaker, 2013). Despite the wide spread use of
PIFU there are very few reports in the literature examining patient views or satisfaction with
such schemes.

87

88 A PIFU scheme was introduced in September 2014 at University Hospitals of Leicester (UHL) 89 for early stage EC. Women who had received a diagnosis of early stage EC in the previous 5 90 years and were under HFU were offered transfer to the PIFU scheme. Women with a new 91 diagnosis were started on PIFU immediately following completion of their treatment. PIFU 92 was led by the CNSs who would have an end of treatment appointment with the patient where 93 they would provide them with their contact details and written information on the 94 signs/symptoms that should prompt a medical review. A telephone call by the CNS to the 95 patient was scheduled for 6 and 12 months to ensure that the patient was still happy to continue 96 on the PIFU scheme and had the contact details should symptoms arise. No other contact with 97 the medical team was organised.

98

In order to ensure patient satisfaction with the scheme a prospective study was conductedinvestigating patients' utilisation, personal opinions and attitudes towards the PIFU scheme.

101

103 **METHODS**

A mixed methods study was undertaken following guidelines for qualitative research in order to ensure reliability and validity (BMJ, 2016). Mixed methods studies are increasingly used within health research to increase our understanding of health problems (Plano Clark & Creswell, 2010). This study utilized a sequential explanatory approach (Terrell, 2012) whereby the results from the distributed questionnaires informed the development of the semi-structured interview schedule. In addition, qualitative data added depth and understanding to the questionnaire findings.

111

The introduction of the PIFU scheme at UHL was supported by the East Midlands Gynaecological Oncology Clinical Advisory Group (ECAG) and the UHL Cancer Board. The prospective audit of patient utility and satisfaction of the scheme was approved by the University Hospitals of Leicester audit team. Ethical approval was granted for the patient interviews (15/WM/0239). Women with a diagnosis of early stage low-risk EC and early stage intermediate risk EC who had completed adjuvant treatment, were enrolled onto the PIFU scheme in its first 18 months (September 2014 to March 2016) and were included in the study.

119

120 Scheme utilisation

Information was collated on the demographics of the patients, including age at diagnosis and ethnicity. The contemporaneous call log and individual patient records kept by the CNSs were reviewed and classified by primary reported reason for telephone contact: physical; psychological; practical. The data were analysed using GraphPad Prism (GraphPad Software, Inc, La Jolla, USA).

126

128 Patient satisfaction

Quality of Life (EORTC QLQ-C30) and patient satisfaction questionnaires (Appendix 1) were posted to the women on the scheme at 6 and 12 months following enrolment. The QLQ-C30 results were analysed using the EORTC QLQ-C30 scoring manual (Fayers & Bjordal, 2001) in order to give a score for Functioning, Symptoms and Global Health Status and were compared against the references values (Scott & Aaronson, 2008).

134

135 Semi-Structured interviews

136 Women enrolled on the PIFU scheme were invited to attend a face-to-face semi-structured 137 interview with two female members of the research team (PK and EM) to discuss their views 138 and opinions on PIFU. Both PK and EM are trained in interview techniques. One of the 139 interviewers was a member of the clinical gynaecological oncology team at the University Hospitals of Leicester. In order to achieve a wide sampling frame women were grouped in to 140 141 British White (BW) (Group a) and non British White (non BW) (Group b) and then subdivided 142 into women who transferred onto the PIFU scheme from HFU (Group A) and those who were 143 started directly onto the PIFU scheme following their diagnosis (Group B). Women were 144 selected randomly from each of the four groups (Aa, Ab, Ba, Bb) by hospital unit number and 145 a written invitation was posted to their home address. Invitations were sent out and interviews 146 were conducted in an outpatients clinic room, until data saturation was achieved. An interview 147 guide was used asking questions on their treatment journey, experiences and views on different 148 follow up schemes and views of the future. Interviews were recorded with the knowledge and 149 consent of the participants and subsequently transcribed verbatim. Due to the interviews being 150 fully transcribed, field notes were not undertaken by either interviewer.

152 The interview data were analysed using the six-stage process of Thematic Analysis described 153 by Braun & Clarke (2006) and managed using Nvivo software. Initially, the analysis was 154 deductive but as the analysis progressed it became more inductive as new themes were 155 identified in the data. The data transcripts were read and re-read to facilitate familiarisation with the data, and then coded line-by-line by the researchers (PK and HM). Repeated reading 156 157 of the data allowed codes to be developed, which were subsequently grouped into themes. As the analysis progressed key themes were selected and further sub-themes were subsequently 158 159 developed. A thematic map incorporating the identified codes was created in order to identify 160 trends and associations. To ensure the trustworthiness of the coding the two researchers (PK 161 and HM) independently coded the data and during discussions similar codes and interpretations 162 were found to have been applied to the cross checked sections of data. All experiences reported 163 by participants were included in the analysis and represented in the manuscript. Triangulation 164 was used at the interpretation stage of the study in order to consider the findings from the 165 quantitative and qualitative aspects and determine their agreement or dissonance (Erzberger & 166 Prein, 1997).

167

168

169 **RESULTS**

Over the 18-month study period 228 women with a diagnosis of an early stage EC were enrolled onto the PIFU scheme. The median age was 65 (range 42 - 90 years). The majority of women, 204 (89.5%), were BW and 24 (10.5%) were non BW (22 British South Asian (BSA) and 2 African/AfroCaribbean (AA)). One hundred and three women were diagnosed pre-September 2014 and were transferred from routine hospital follow-up (HFU) onto the PIFU scheme. There were 125 women diagnosed post-September 2014 that were directly transferred onto the PIFU scheme. The median time on the PIFU scheme was 14 months (95% CI 12.914.3 months). The total number of women in follow-up prior to September 2014 or who had
completed adjuvant therapy was not known and therefore it was not possible to calculate the
proportion of patients who moved to PIFU. Women in these groups were given the choice of
PIFU rather than HFU by their supervising clinicians. Of the women diagnosed post-September
2014 with early stage low-risk EC less than 5% were deemed not suitable for recruitment to
PIFU, primarily due to mental health issues.

183

184 Patient-Initiated Contact

185 Forty-five women (19.7%) contacted the Clinical Nurse Specialists (CNS) at least once. 186 Significantly more contact was made in the first six months of being entered onto the scheme 187 as compared to the second six months (37/45 versus 8/45, Chi squared p<0.001). Women who 188 were transferred onto PIFU directly also were more likely to make contact compared to women 189 who had been under routine HFU and then transferred (30/125 women versus 15/103 women, 190 Chi square p=0.075) and were significantly younger than women who did not contact (median 191 age 57 years compared to 65 years, Mann Whitney p<0.001). Although women of non BW 192 ethnicity were more likely to contact (6/24, 33.3%) compared to BW women (39/204, 19.1%) 193 the difference was not statistically significant. Four women were transferred from PIFU back 194 to HFU due to patient anxiety and multiple symptomatology.

195

The primary reason for contacting the CNS were mainly due to physical symptoms (62%), such as vaginal bleeding/discharge or abdominal pain, however, 20% of the calls were for psychological support or reassurance. Another 2 calls were for practical assistance, for example help claiming benefits.

200

202 Quality of Life

In total, 153 6-month and 109 12-month Quality of Life (QLQ) and Patient Satisfaction (PSQ) 203 204 questionnaires were returned. There was no significant difference in Functioning Scale Scores 205 (FSS) between the six-month and 12-month QLQs (Figure 1). For all of the functioning 206 subscales, the scores from both 6 and 12 months were higher than the references values, 207 indicating that the women on the PIFU scheme had a higher level of functioning than the 208 reference populations 'all cancer patients: female' and 'all cancer patients: stage 1-II'. The 209 scores were also lower than the reference values for the symptoms scale score (SSS) (Figure 210 2) and for the global health status score (GHSS) (Figure 3). There was no difference in the 211 GHSS score between the 6- and 12-month QLQs, Mann Whitney p=0.564.

212

213 Patient Satisfaction

214 Patient feedback regarding the PIFU scheme was positive, with 62% of women in the 6-month 215 PSQ reported they found it useful (very much/quite a bit) and only one patient (0.6%) reporting 216 that they did not find the scheme useful at all. Dissatisfaction increased slightly at the 12-month 217 PSQ with 4 women (3.6%) giving the response 'not at all' to the question 'Overall how 218 reassured are you by PIFU?' but this contrasted with 63% of women who responded very 219 much/quite a bit. In the PSQs 25 women (six-month PSQ) and 12 women (12-month PSQ) 220 reported contacting the CNS with the most common reason being that they were worried about 221 a symptom they had developed. The next most commonly reported reason was that they wanted 222 to speak about worries and feelings that they were having.

223

224 Patient Attitudes

Of the 51 women contacted, 21 women agreed to (13 BW and 8 non BW) participate in a semistructured interview. Non BW women were offered translators, which two accepted and two women brought a family member with them to translate. Interview times ranged from 20 to 58minutes.

229

230 PIFU was reported as being the preferred follow-up model by nine women. Four women 231 preferred HFU and five suggested a combination of HFU initially following treatment with 232 transfer to PIFU after a short period of time, for example 12 months, would be better. Women 233 that preferred the PIFU scheme commented on the importance of being able to carry on with 234 their lives and being able to have more control over their own health whilst having the 235 reassurance of direct access to the CNS if needed. For example, one 53-year-old non BW 236 female stated; "It stops me having to worry about 'I've got an appointment here to come and 237 see this person'. I'm looking out for my own symptoms and know that if I ring up the secretary 238 or the clinic and say 'I have this issue, can I come and see somebody?' I can come in. I don't 239 have to go via the GP is what I'm saving." The main reason given for preferring hospital 240 follow-up (HFU) was the reassurance of seeing somebody face-to-face as it was thought to be 241 more personal. A 51-year-old BW female said; "I think I would have preferred to come back 242 and seen, physically seen someone... I think it's more just reassurance to meet somebody face 243 to face about it. It's a bit more personal." No participants reported that they would have 244 preferred to be seen by their general practitioner (GP) for follow-up.

245

The majority of women on the PIFU scheme understood how to use the scheme. The overall feeling reported by participants was that it was easier and quicker to contact the CNS and they reported that they had confidence that the CNS would instigate any necessary investigations or appointments, rather than being seen in primary care for symptoms. The majority of the non BW women interviewed were of BSA ethnicity and they felt particularly reassured that they could communicate with a Gujarati/Hindi speaking CNS. A 59-year old non BW female said;

Yes. It's very helpful because it's in our language, whatever the problem is I can communicate
it very well and I'm happy".

254

The main reason participants reported for not utilising the scheme was the fear of wasting the CNS' time. For example, a 63 year-old BW female stated; "*It's too easy to think 'I won't bother' because it, I don't know, you feel like you're bothering somebody.*" Other reported reasons included either worrying about or ignoring symptoms participants thought might have been related to their endometrial cancer diagnosis. For example, a 53-year old non BW female said; "The only barrier that I think would stop them ringing in is if they worried that it has *come back. Because you've got to get your mind around that one first before you go and ring*".

Wasting the doctor's time' and the 'unnecessary journey' to a HFU appointment if women were asymptomatic were commonly reported barriers to attending HFU. A 63 year-old BW female said; 'It becomes a bit of a pain coming in every 4 months, every 6 months, when actually there's not anything wrong with you and it's a waste of your time, bus money, petrol money, whatever the consultant's time, when there's actually nothing wrong with you.'

268

269 **DISCUSSION**

Risk stratification with regard to patient follow-up is not a new concept in oncology. PIFU schemes have been developed for low-risk disease for several reasons, both patient and economic, across a range of specialties and diseases (Taneja, Su'a, & Hill, 2014). However, ensuring patient safety and satisfaction has to be the central goal when evaluating such schemes. In this mixed methods study we have used both quantitative and qualitative methods to ensure women are utilising PIFU and are accessing the CNSs when needed. The results of the two investigative methods have given complimentary information, with the quantitative aspect determining the frequency/indication for contact and the interviews exploring women's
rationale for their behavior. Leeson et al., (Leeson et al., 2013) identified that there are a wide
range of follow-up models currently in use in the UK for women who have been diagnosed
with a gynaecological malignancy. Many centres reported using telephone (25%) or patientinitiated (32%) follow up schemes, in contrast to ESMO guidance (Colombo et al., 2011),
which supports a policy of regular follow up for all patients for 5 years.

283

284 We have demonstrated that early stage EC patients experience a good quality of life post 285 treatment, noticeably higher than the reference populations 'all cancer patients: female' and 286 'all cancer patients: stage I-II' used for the EORTC-QLQ30. A strong theme that emerged in 287 the interviews was that women understood that their risk of recurrence was low and did not 288 want to keep being reminded of their diagnosis by attending HFU. This may be interpreted as 289 a self-management coping mechanism whereby the participants tried to leave their cancer 290 experiences behind them in an attempt to adopt some form of normality. Indeed, reminders of 291 cancer have been found to induce fear and increased insecurity of cancer recurrence in breast 292 cancer survivors (Drageset, Lindstrom, & Underlid, 2016).

293

294 The fear of cancer recurrence can lead to cancer survivors employing specific self-management 295 strategies to forget their cancer diagnosis. Howard et al., (Howard et al., 2016) identified that 296 adult childhood cancer survivors' employed strategies such as avoiding contact with medical 297 personnel and not attending hospital/clinic appointments in an attempt to forget their previous 298 diagnosis. In a further study by Zelman et al., (Zelman et al., 2004) participants reported that 299 being able to forget about their cancer diagnosis, even for a short while, was an important 300 determinant of a 'desirable day'. Returning to normal life has been identified as a highly 301 motivating factor for recovery (Howard et al., 2016) and an important factor in coping with a 302 cancer diagnosis (Drageset, Lindstrom, & Underlid, 2010). PIFU removes the need for patients 303 to attend hospital appointments and it may be argued that this can facilitate their 'return to 304 normal'. The good long-term prognosis of early stage EC and PIFU can help to change 305 people's perception that cancer is not necessarily a fatal disease but that they can have a life 306 beyond their diagnosis. The change in focus toward patient survivorship is increasingly 307 necessary and the importance of developing supported self-management pathways, helping 308 patients to manage their own health and wellbeing can not only address unmet needs but can 309 reduce the demand on support services.

310

311 We have shown that PIFU for early stage EC is well received by our population. A recent 312 randomised trial evaluating the effectiveness of nurse-led telephone follow-up (NTFU), 313 compared to HFU, also reported high levels of patient satisfaction, with no detrimental physical 314 or psychological effects (Beaver et al., 2016). Our scheme was not classified as a NTFU since 315 the 6-monthly calls were not structured and did not ask questions on symptoms or wellbeing, 316 merely ensured that the patient understood the purpose of the PIFU scheme and was happy to 317 remain on it. We did identify that younger women and women from a non BW ethnicity were 318 more likely to initiate contact, suggesting that they were in greater need of support from the 319 CNS. A reason for this finding could be that psychological unmet needs have been shown to 320 be significantly associated with age at diagnosis (Boyes, Girgis, D'Este, & Zucca, 2012). BSA 321 cancer patients are reported to have twice the rate of self-reported depressive symptoms and 322 five times the incidence of severe depression as compared to BW cancer patients (Lord et al., 323 2013). Lord et al., (Lord et al., 2013) also reported that BSA patients used more maladaptive 324 coping strategies, such as helplessness/hopelessness and fatalism, and experienced a heavier 325 physical symptom burden as compared to BW patients. In our study the BSA women reported 326 that they were very supportive of PIFU preferring not to attend the hospital, since this was felt 327 to be a sign of ongoing active disease rather than surveillance for disease that had been treated. 328 It is essential when designing a PIFU scheme to ensure that the women who are enrolled have 329 the capacity and insight to contact the CNS should an issue arise. Women who are non-English 330 speakers are at particular risk of being disenfranchised and education sessions with their 331 family/carers and the availability of interpreting services can enable women to participate in 332 PIFU. Knowledge of the local community and its demographics can be helpful in planning 333 services, for example Leicester has a high BSA population who are predominantly Gujarati 334 speaking. An advantage of the Leicester PIFU scheme therefore is that one of the CNSs is a 335 fluent Gujarati/Hindi speaker thereby enabling non-English speakers to access the scheme, 336 another positive factor reported by the non BW women who were interviewed.

337

338 CONCLUSION

PIFU for early stage EC appears to be well received by the majority of women. Although many of the CNS contacts were related to physical symptoms, many were for psychological support or reassurance. Younger women had greater CNS contact indicating that they may benefit from a greater level of CNS support. Women from a non WB ethnicity are also supportive of PIFU, although consideration should be made to ensure non-fluent English speakers are able to access the scheme.

345

355


356

- 358 **REFERENCES**
- 359
- 360
- Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I.
 (2005). Endometrial cancer. *Lancet*, *366*(9484), 491-505. doi:10.1016/S0140 6736(05)67063-8
- Beaver, K., Williamson, S., Sutton, C., Hollingworth, W., Gardner, A., Allton, B., ...
 Martin-Hirsch, P. (2016). Comparing hospital and telephone follow-up for patients
 treated for stage-I endometrial cancer (ENDCAT trial): a randomised, multicentre,
 non-inferiority trial. *BJOG*. doi:10.1111/1471-0528.14000
- BMJ Editor's checklists 2016 [cited 2016 1 April]. Available from:
 http://www.bmj.com/about-bmj/resources-authors/article-types/research/editors checklists.
- Boyes, A. W., Girgis, A., D'Este, C., & Zucca, A. C. (2012). Prevalence and correlates of
 cancer survivors' supportive care needs 6 months after diagnosis: a population-based
 cross-sectional study. *BMC Cancer*, *12*, 150. doi:10.1186/1471-2407-12-150
- Colombo, N., Preti, E., Landoni, F., Carinelli, S., Colombo, A., Marini, C., . . . Group, E. G.
 W. (2011). Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis,
 treatment and follow-up. *Ann Oncol, 22 Suppl 6*, vi35-39.
 doi:10.1093/annonc/mdr374
- 378 Drageset, S., Lindstrom, T. C., & Underlid, K. (2010). Coping with breast cancer: between
 379 diagnosis and surgery. *J Adv Nurs*, 66(1), 149-158. doi:10.1111/j.1365 380 2648.2009.05210.x
- 381 Drageset, S., Lindstrom, T. C., & Underlid, K. (2016). "I just have to move on": Women's
 382 coping experiences and reflections following their first year after primary breast
 383 cancer surgery. *Eur J Oncol Nurs*, 21, 205-211. doi:10.1016/j.ejon.2015.10.005
- Erzberger, C., & Prein, G. (1997). Triangulation: Validity and empirically-based hypothesis
 construction. *Quality & Quantity*, 31(2), 141-154.
- Fayers, P., & Bjordal, K. (2001). *EORTC QLQ-C30 scoring manual* (3rd ed.). Brussels:
 EOTOC Publications.
- Gadducci, A., Cosio, S., Fanucchi, A., Cristofani, R., & Genazzani, A. R. (2000). An
 intensive follow-up does not change survival of patients with clinical stage I
 endometrial cancer. *Anticancer Res, 20*(3B), 1977-1984.
- Howard, A. F., Goddard, K., Tan de Bibiana, J., Pritchard, S., Olson, R., & Kazanjian, A.
 (2016). Adult childhood cancer survivors' narratives of managing their health: the
 unexpected and the unresolved. *J Cancer Surviv*, 10(4), 711-725.
 doi:10.1007/s11764-016-0517-8
- Leeson, S., Stuart, N., Sylvestre, Y., Hall, L., & Whitaker, R. (2013). Gynaecological cancer
 follow-up: national survey of current practice in the UK. *BMJ Open*, *3*(7).
 doi:10.1136/bmjopen-2013-002859
- Lord, K., Ibrahim, K., Kumar, S., Mitchell, A. J., Rudd, N., & Symonds, R. P. (2013). Are
 depressive symptoms more common among British South Asian patients compared
 with British White patients with cancer? A cross-sectional survey. *BMJ open*, 3(6),
 e002650.
- 402 Owen, P., & Duncan, I. D. (1996). Is there any value in the long term follow up of women
 403 treated for endometrial cancer? *Br J Obstet Gynaecol*, *103*(7), 710-713.
- Parkin, D. M., Boyd, L., & Walker, L. C. (2011). 16. The fraction of cancer attributable to
 lifestyle and environmental factors in the UK in 2010. *Br J Cancer*, *105 Suppl 2*, S77doi:10.1038/bjc.2011.489


407	Plano Clark, V., & Creswell, J. (2010). Understanding research: a consumer's guide. Upper
408	Saddle River, NJ: Prentice Hall - Merrill.
409	Salani, R., Backes, F. J., Fung, M. F., Holschneider, C. H., Parker, L. P., Bristow, R. E., &
410	Goff, B. A. (2011). Posttreatment surveillance and diagnosis of recurrence in women
411	with gynecologic malignancies: Society of Gynecologic Oncologists
412	recommendations. Am J Obstet Gynecol, 204(6), 466-478.
413	doi:10.1016/j.ajog.2011.03.008

- 414 Scott, N., & Aaronson, N. (2008). EORTC QLQ-C30 Reference Values. Brussels: EORTC
 415 Publications.
- Taneja, A., Su'a, B., & Hill, A. G. (2014). Efficacy of patient-initiated follow-up clinics in
 secondary care: a systematic review. *Intern Med J*, 44(12a), 1156-1160.
 doi:10.1111/imj.12533
- 419 UK, C. R. Survival statistic for womb cancer | Cancer Research UK. Cancerresearchuk.org.
 420 2016 [cited 12 July 2016]. Available from: <u>http://www.cancerresearchuk.org/about-</u>
 421 <u>cancer/type/womb-cancer/treatment/statistics-and-outlook-for-womb-cancer#prog.</u>
- 422 UK, C. R. Uterine cancer incidence statistics 2016 [cited 2016 13 May]. Available from:
 423 <u>http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-</u>
 424 <u>cancer-type/uterine-cancer/incidence#heading-Two</u>.
- Yoshiba, T., Takei, Y., Machida, S., Taneichi, A., Sato, N., Takahashi, S., . . . Fujiwara, H.
 (2016). Prognosis of endometrial cancer patients with and without symptoms at recurrence. *J Obstet Gynaecol Res.* doi:10.1111/jog.13112
- Zelman, D. C., Smith, M. Y., Hoffman, D., Edwards, L., Reed, P., Levine, E., ... Dukes, E.
 (2004). Acceptable, manageable, and tolerable days: patient daily goals for
 medication management of persistent pain. *J Pain Symptom Manage*, 28(5), 474-487.
- 431 doi:10.1016/j.jpainsymman.2004.02.022

- -**T-T** I



495 Figure 2. Symptoms scale score (SSS).
496
497
498 A) Pain
499 6 months n=145, 12 months n=105. Mann Whitney p=0.429
500
501





 521
 B) Fatigue

 522
 6 months

- 6 months n=146, 12 months n=104. Mann Whitney p=0.250




Figure 3. EORTC Global Health Status Scores (GHSS). Range from 0-100 with a high score

540 indicating a high quality of life. 6 months n=146, 12 months n=106. Mann Whitney p=0.564.
541

